Important effect of food on the bioavailability of oral testosterone undecanoate

被引:62
作者
Bagchus, WM
Hust, R
Maris, F
Schnabel, PG
Houwing, NS
机构
[1] Organon, Dept Clin Pharmacol, NL-5340 BH Oss, Netherlands
[2] Organon, Dept Drug Metab & Kinet, NL-5340 BH Oss, Netherlands
[3] Focus Clin Drug Dev GMBH, Neuss, Germany
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 03期
关键词
D O I
10.1592/phco.23.3.319.32104
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To assess the effects of food on the bioavailability of testosterone undecanoate, testosterone, and 5alpha-dihydrotestosterone (DHT) after administration of a new oral testosterone undecanoate formulation, Andriol Testocaps. Design. Randomized, open-label, crossover study with a 1-week washout period. Setting. Clinical pharmacology unit. Subjects. Sixteen healthy postmenopausal women. Intervention. Single oral doses of testosterone undecanoate 80 mg were administered either during a fasting period or after consumption of a standardized continental breakfast. Measurements and Main Results. Serum concentrations of testosterone undecanoate were assayed by liquid chromatography with mass spectrometry detection; testosterone and DHT were assayed by gas chromatography with mass spectrometry detection. Serum concentrations of testosterone, testosterone undecanoate, and DHT were low to negligible when testosterone undecanoate was administered to subjects in a fasting state; these values were significantly higher when the test drug was coadministered with food. For testosterone, the maximum serum concentration and area under the plasma concentration-time curve were 0.67 ng/ml and 5.37 ng.hr/ml, respectively, in the fasting state, versus 10.7 ng/ml and 56.4 ng.hr/ml, respectively, in the fed state. The same parameters were also significantly higher for testosterone undecanoate and DHT in the fed versus fasting subjects. Conclusion. Food increases the bioavailability of testosterone undecanoate, testosterone, and DHT. For proper absorption, Andriol Testocaps must be taken with meals.
引用
收藏
页码:319 / 325
页数:7
相关论文
共 8 条
  • [1] WHICH TESTOSTERONE REPLACEMENT THERAPY
    CANTRILL, JA
    DEWIS, P
    LARGE, DM
    NEWMAN, M
    ANDERSON, DC
    [J]. CLINICAL ENDOCRINOLOGY, 1984, 21 (02) : 97 - 107
  • [2] Lipophilic prodrugs designed for intestinal lymphatic transport
    Charman, WN
    Porter, CJH
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1996, 19 (02) : 149 - 169
  • [3] BIOAVAILABILITY OF ORAL TESTOSTERONE IN MALES
    FREY, H
    AAKVAAG, A
    SAANUM, D
    FALCH, J
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (05) : 345 - 349
  • [4] Geurts T. B. P., 2000, J UROL UROGENAKOL, P24
  • [5] TESTOSTERONE UNDECANOATE - NEW ORALLY ACTIVE ANDROGEN
    HIRSCHHAUSER, C
    HOPKINSON, CRN
    STURM, G
    COERT, A
    [J]. ACTA ENDOCRINOLOGICA, 1975, 80 (01): : 179 - 187
  • [6] LYMPHATIC ABSORPTION AND METABOLISM OF ORALLY-ADMINISTERED TESTOSTERONE UNDECANOATE IN MAN
    HORST, HJ
    HOLTJE, WJ
    DENNIS, M
    COERT, A
    GEELEN, J
    VOIGT, KD
    [J]. KLINISCHE WOCHENSCHRIFT, 1976, 54 (18): : 875 - &
  • [7] A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine
    Khoo, SM
    Edwards, GA
    Porter, CJH
    Charman, WN
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (10) : 1599 - 1607
  • [8] THE EFFECT OF DRUG LIPOPHILICITY AND LIPID VEHICLES ON THE LYMPHATIC ABSORPTION OF VARIOUS TESTOSTERONE ESTERS
    NOGUCHI, T
    CHARMAN, WNA
    STELLA, VJ
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1985, 24 (2-3) : 173 - 184